JP2015071598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015071598A5 JP2015071598A5 JP2014205331A JP2014205331A JP2015071598A5 JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5 JP 2014205331 A JP2014205331 A JP 2014205331A JP 2014205331 A JP2014205331 A JP 2014205331A JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- vaccine
- antigen complex
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8123408P | 2008-07-16 | 2008-07-16 | |
| US61/081,234 | 2008-07-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Division JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015071598A JP2015071598A (ja) | 2015-04-16 |
| JP2015071598A5 true JP2015071598A5 (cg-RX-API-DMAC7.html) | 2015-05-28 |
| JP6109800B2 JP6109800B2 (ja) | 2017-04-05 |
Family
ID=41551022
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Expired - Fee Related JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン |
| JP2014205331A Expired - Fee Related JP6109800B2 (ja) | 2008-07-16 | 2014-10-06 | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Expired - Fee Related JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン |
Country Status (19)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| JP2012501323A (ja) * | 2008-08-29 | 2012-01-19 | アカデミシュ ジーケンハウス ライデン ハー.オー.デー.エン. ルムク | 対象の腫瘍流入領域リンパ節へのcd40アゴニストの送達 |
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| BRPI1009455A2 (pt) | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
| WO2011032161A2 (en) * | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
| JP5628544B2 (ja) * | 2010-04-07 | 2014-11-19 | 株式会社豊田中央研究所 | クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用 |
| CA2798616A1 (en) | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| US20120128710A1 (en) * | 2010-11-02 | 2012-05-24 | Baylor Research Institute | Enhancement of Pathogen-Specific Memory Th17 Cell Responses |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| US20120301465A1 (en) * | 2011-03-25 | 2012-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods to immunize against hepatitis c virus |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014039840A1 (en) * | 2012-09-07 | 2014-03-13 | Baylor Research Institute | Hiv vaccine compositions and methods |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| WO2014210540A1 (en) | 2013-06-28 | 2014-12-31 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| WO2015106281A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| CN105821030A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 表达α1,3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| US20180356398A1 (en) | 2017-06-09 | 2018-12-13 | Fujifilm Corporation | Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance |
| WO2019031938A2 (ko) | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020162696A1 (ko) | 2019-02-08 | 2020-08-13 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| KR20220131895A (ko) * | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| CA3184802A1 (en) | 2020-05-26 | 2021-12-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| JP2023554587A (ja) | 2020-11-12 | 2023-12-28 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 |
| GB202019879D0 (en) * | 2020-12-16 | 2021-01-27 | Ucl Business Ltd | Polypeptide |
| US20240131138A1 (en) | 2020-12-23 | 2024-04-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| JP2024540505A (ja) | 2021-11-17 | 2024-10-31 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ユニバーサルサルベコウイルスワクチン |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| CN119948059A (zh) | 2022-10-05 | 2025-05-06 | 法国国家健康医学研究院 | 靶向dc的抗尼帕病毒感染疫苗 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3949064A (en) | 1973-10-26 | 1976-04-06 | Baxter Laboratories, Inc. | Method of detecting antigens or antibodies |
| US4174384A (en) | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU7275698A (en) * | 1998-05-01 | 1999-11-23 | Procter & Gamble Company, The | Laundry detergent and/or fabric care compositions comprising a modified antimicrobial protein |
| WO2000000156A2 (en) | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
| JP2000157282A (ja) * | 1998-11-30 | 2000-06-13 | Toyota Central Res & Dev Lab Inc | 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素 |
| HUP0300997A2 (hu) * | 2000-03-23 | 2003-07-28 | Akzo Nobel N.V. | A MIA-fehérje alkalmazása immunterápiában |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2002090510A2 (en) | 2001-05-08 | 2002-11-14 | Emory University | Regulating immine responses using dendritic cells |
| GB0118367D0 (en) | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
| RU2312896C2 (ru) * | 2001-09-20 | 2007-12-20 | Глаксо Груп Лимитед | Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида |
| EP1441030A4 (en) | 2001-10-11 | 2007-08-15 | Katakura Ind Co Ltd | PROCESS FOR CLEANING A RECOMBINANT FUSION PROTEIN AND METHOD FOR PRODUCING PROTEIN THEREWITH |
| CA2468878A1 (en) * | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation |
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| JP2004236504A (ja) | 2003-02-03 | 2004-08-26 | Toyota Central Res & Dev Lab Inc | 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素 |
| JP2005143444A (ja) | 2003-11-19 | 2005-06-09 | Lion Corp | キメラ酵素及び洗浄剤組成物 |
| SI1771474T1 (sl) * | 2004-07-20 | 2010-06-30 | Genentech Inc | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2575163A1 (en) | 2004-08-09 | 2006-02-23 | Merck & Co., Inc. | Adenoviral vector compositions |
| BRPI0518933A2 (pt) * | 2004-11-16 | 2008-12-16 | Crucell Holland B V E Aeras Gl | adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium |
| EP1752533A1 (en) | 2005-08-12 | 2007-02-14 | Institut National de la Recherche Agronomique | Fusion proteins between plant cell-wall degrading enzymes, and their uses |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
-
2009
- 2009-07-16 WO PCT/US2009/050903 patent/WO2010009346A2/en not_active Ceased
- 2009-07-16 EP EP09798772A patent/EP2307048A4/en not_active Withdrawn
- 2009-07-16 NZ NZ594540A patent/NZ594540A/en not_active IP Right Cessation
- 2009-07-16 DK DK15182056.0T patent/DK2966091T3/en active
- 2009-07-16 PT PT151820560T patent/PT2966091T/pt unknown
- 2009-07-16 US US12/504,463 patent/US9109011B2/en active Active
- 2009-07-16 CA CA2730742A patent/CA2730742C/en active Active
- 2009-07-16 KR KR1020117003562A patent/KR20110036618A/ko not_active Ceased
- 2009-07-16 MY MYPI2011000174A patent/MY155377A/en unknown
- 2009-07-16 EP EP15182056.0A patent/EP2966091B1/en active Active
- 2009-07-16 NZ NZ590628A patent/NZ590628A/en not_active IP Right Cessation
- 2009-07-16 MX MX2011000507A patent/MX2011000507A/es active IP Right Grant
- 2009-07-16 KR KR1020137016705A patent/KR101548143B1/ko not_active Expired - Fee Related
- 2009-07-16 NZ NZ596171A patent/NZ596171A/xx not_active IP Right Cessation
- 2009-07-16 CN CN200980136014.3A patent/CN102625714B/zh not_active Expired - Fee Related
- 2009-07-16 ES ES18173658T patent/ES2890230T3/es active Active
- 2009-07-16 BR BRPI0915915A patent/BRPI0915915A2/pt not_active IP Right Cessation
- 2009-07-16 RU RU2011105119/10A patent/RU2539765C2/ru not_active IP Right Cessation
- 2009-07-16 AP AP2011005541A patent/AP2011005541A0/xx unknown
- 2009-07-16 AU AU2009270771A patent/AU2009270771B2/en not_active Ceased
- 2009-07-16 JP JP2011518925A patent/JP5984388B2/ja not_active Expired - Fee Related
- 2009-07-16 ES ES15182056.0T patent/ES2685823T3/es active Active
- 2009-07-16 EP EP18173658.8A patent/EP3388450B1/en active Active
-
2011
- 2011-01-13 IL IL210646A patent/IL210646A0/en unknown
- 2011-01-14 ZA ZA2011/00398A patent/ZA201100398B/en unknown
-
2012
- 2012-12-10 RU RU2012153053/10A patent/RU2012153053A/ru not_active Application Discontinuation
-
2014
- 2014-10-06 JP JP2014205331A patent/JP6109800B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011105119A (ru) | Вич вакцина, основанная на направленности максимизированных gag и nef на дендритные клетки | |
| Idoyaga et al. | Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A | |
| Birkholz et al. | Targeting of DEC-205 on human dendritic cells results in efficient MHC class II–restricted antigen presentation | |
| Trumpfheller et al. | The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | |
| TW201200150A (en) | Dendritic cell immunoreceptors (DCIR)-mediated crosspriming of human CD8+ T cells | |
| CN101679508B (zh) | 基于靶向抗原至抗原呈递细胞上表达的dcir的疫苗 | |
| AU2010291939B2 (en) | Vaccines directed to Langerhans cells | |
| JP2010518024A5 (cg-RX-API-DMAC7.html) | ||
| US20250388636A1 (en) | T-cell expansion method and uses | |
| US9885017B2 (en) | Compositions and methods to immunize against hepatitis C virus | |
| Epaulard et al. | Macrophage-and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses | |
| TW201305193A (zh) | 靶向結核病(tb)疫苗之樹突細胞(dc) | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| WO2012122396A1 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| RU2013110889A (ru) | Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки | |
| JP2013535508A5 (cg-RX-API-DMAC7.html) | ||
| JP2010518024A (ja) | 樹状細胞アシアロ糖タンパク質受容体(dc−asgpr)を介して抗原提示細胞に結合する作用物質 | |
| JP2023528017A5 (cg-RX-API-DMAC7.html) | ||
| Apostolico et al. | Dendritic cell targeting effectively boosts T cell responses elicited by an HIV multiepitope DNA vaccine | |
| JP2023554587A5 (cg-RX-API-DMAC7.html) | ||
| US20130017151A1 (en) | SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS | |
| You et al. | Priming of Autoreactive CD8+ T Cells Is Inhibited by Immunogenic Peptides Which Are Competitive for Major Histocompatibility Complex Class I Binding | |
| Brody et al. | Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant | |
| US10226518B2 (en) | Ubiquitinylated proteins | |
| Lim et al. | A GD Type of Cancel Culture |